Myxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28B
Carregando...
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2013
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Autores
ANGELO, Ana Luiza Dias
CAVALCANTE, Lourianne Nascimento
ABE-SANDES, Kiyoko
MACHADO, Taisa Bonfim
LEMAIRE, Denise Carneiro
LYRA, Luiz Guilherme Costa
LYRA, Andre Castro
Citação
CLINICS, v.68, n.10, p.1325-1332, 2013
Resumo
OBJECTIVES: Suppressor of cytokine signaling 3, myxovirus resistance protein and osteopontin gene polymorphisms may influence the therapeutic response in patients with chronic hepatitis C, and an association with IL28 might increase the power to predict sustained virologic response. Our aims were to evaluate the association between myxovirus resistance protein, osteopontin and suppressor of cytokine signaling 3 gene polymorphisms in combination with IL28B and to assess the therapy response in hepatitis C patients treated with pegylated-interferon plus ribavirin. METHOD: Myxovirus resistance protein, osteopontin, suppressor of cytokine signaling 3 and IL28B polymorphisms were analyzed by PCR-restriction fragment length polymorphism, direct sequencing and real-time PCR. Ancestry was determined using genetic markers. RESULTS: We analyzed 181 individuals, including 52 who were sustained virologic responders. The protective genotype frequencies among the sustained virologic response group were as follows: the G/G suppressor of cytokine signaling 3 (rs4969170) (62.2%); T/T osteopontin (rs2853744) (60%); T/T osteopontin (rs11730582) (64.3%); and the G/T myxovirus resistance protein (rs2071430) genotype (54%). The patients who had >= 3 of the protective genotypes from the myxovirus resistance protein, the suppressor of cytokine signaling 3 and osteopontin had a greater than 90% probability of achieving a sustained response (p < 0.0001). The C/C IL28B genotype was present in 58.8% of the subjects in this group. The sustained virological response rates increased to 85.7% and 91.7% by analyzing C/C IL28B with the T/T osteopontin genotype at rs11730582 and the G/G suppressor of cytokine signaling 3 genotype, respectively. Genetic ancestry analysis revealed an admixed population. CONCLUSION: Hepatitis C genotype 1 patients who were responders to interferon-based therapy had a high frequency of multiple protective polymorphisms in the myxovirus resistance protein, osteopontin and suppressor of cytokine signaling 3 genes. The combined analysis of the suppressor of cytokine signaling 3 and IL28B genotypes more effectively predicted sustained virologic response than IL28B analysis alone.
Palavras-chave
Hepatitis C, IL28B, Osteopontin, SOCS3, Genetic polymorphisms
Referências
- Abe H, 2011, J HEPATOL, V54, P1094, DOI 10.1016/j.jhep.2010.09.019
- BATZER MA, 1994, P NATL ACAD SCI USA, V91, P12288, DOI 10.1073/pnas.91.25.12288
- Bode JG, 2003, FASEB J, V17, P488, DOI 10.1096/fj.02-0664fje
- Bonilla C, 2004, ANN HUM GENET, V68, P139, DOI 10.1046/j.1529-8817.2003.00084.x
- Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473
- Cavalcante LN, 2012, LIVER INT, V32, P476, DOI 10.1111/j.1478-3231.2011.02653.x
- Chakraborty R., 1985, GENETIC MICRODIFFERE, P171
- David M, 2002, BIOTECHNIQUES, P58
- Divers J, 2007, GENETICS, V176, P1823, DOI 10.1534/genetics.107.075408
- Fernandez M, 1999, J INFECT DIS, V180, P262, DOI 10.1086/314859
- Gad HH, 2009, J BIOL CHEM, V284, P20869, DOI 10.1074/jbc.M109.002923
- Ge DL, 2009, NATURE, V461, P399, DOI 10.1038/nature08309
- Goodbourn S, 2000, J GEN VIROL, V81, P2341
- Hijikata M, 2001, INTERVIROLOGY, V44, P379, DOI 10.1159/000050075
- Knapp S, 2003, GENES IMMUN, V4, P411, DOI 10.1038/sj.gene.6363984
- Mabee CL, 1998, ALIMENT PHARM THERAP, V12, P509
- Miyaaki H, 2009, HEPATOL RES, V39, P850, DOI 10.1111/j.1872-034X.2009.00529.x
- Mochida S, 2004, BIOCHEM BIOPH RES CO, V313, P1079, DOI 10.1016/j.bbrc.2003.12.045
- Naito M, 2005, J GASTROENTEROL, V40, P381, DOI 10.1007/s00535-005-1558-3
- Parra EJ, 1998, AM J HUM GENET, V63, P1839, DOI 10.1086/302148
- Persico M, 2008, GUT, V57, P507, DOI 10.1136/gut.2007.129478
- RAYMOND M, 1995, J HERED, V86, P248
- Shriver MD, 2003, HUM GENET, V112, P387, DOI 10.1007/s00439-002-0896-y
- Tanaka Y, 2009, NAT GENET, V41, P1105, DOI 10.1038/ng.449
- Thio CL, 2008, CLIN LIVER DIS, V12, P713, DOI 10.1016/j.cld.2008.03.002
- Thomas DL, 2009, NATURE, V461, P798, DOI 10.1038/nature08463
- Welzel TM, 2009, HEPATOLOGY, V49, P1847, DOI 10.1002/hep.22877
- YAMAMOTO S, 1995, ANN NY ACAD SCI, V760, P44, DOI 10.1111/j.1749-6632.1995.tb44619.x
- Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143